These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 32987122)
1. Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding. Shin J; Phelan PJ; Gjoerup O; Bachovchin W; Bullock PA Protein Expr Purif; 2021 Jan; 177():105766. PubMed ID: 32987122 [TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab. Roither B; Oostenbrink C; Schreiner W BMC Bioinformatics; 2020 Dec; 21(Suppl 17):557. PubMed ID: 33308148 [TBL] [Abstract][Full Text] [Related]
3. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability. Fujiwara K; Shigematsu K; Tachibana M; Okada N IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257 [TBL] [Abstract][Full Text] [Related]
4. Rational design of a Nivolumab-based ANTI-PD-1 single chain variable fragment that blocks the interaction between PD-1 expressed on T-CELLS and PD-L1 ON CHO cells. Shin J; Raissi S; Phelan P; Bullock PA Protein Expr Purif; 2023 Feb; 202():106196. PubMed ID: 36280166 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the cyclic single-chain Fv antibody derived from nivolumab by biophysical analyses and in vitro cell-based bioassay. Kamesawa S; Ogawa M; Funakoshi Y; Kato M; Kai S; Namikawa M; Okazaki K; Sato T; Kobashigawa Y; Morioka H J Biochem; 2024 Jul; 176(2):131-138. PubMed ID: 38591885 [TBL] [Abstract][Full Text] [Related]
6. Exploring the conformational dynamics of PD1 in complex with different ligands: What we can learn for designing novel PD1 signaling blockers? Ponce LF; García-Martínez K; León K; Valiente PA Proteins; 2021 Feb; 89(2):141-148. PubMed ID: 32862461 [TBL] [Abstract][Full Text] [Related]
7. Blockade of the checkpoint PD-1 by its ligand PD-L1 and the immuno-oncological drugs pembrolizumab and nivolumab. Tavares ABMLA; Lima Neto JX; Fulco UL; Albuquerque EL Phys Chem Chem Phys; 2021 Sep; 23(37):21207-21217. PubMed ID: 34533552 [TBL] [Abstract][Full Text] [Related]
8. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162 [TBL] [Abstract][Full Text] [Related]
9. Production of a recombinant anti-human CD4 single-chain variable-fragment antibody using phage display technology and its expression in Escherichia coli. Babaei A; Zarkesh-Esfahani SH; Gharagozloo M J Microbiol Biotechnol; 2011 May; 21(5):529-35. PubMed ID: 21617352 [TBL] [Abstract][Full Text] [Related]
10. Improved soluble expression of a single-chain antibody fragment in E. coli for targeting CA125 in epithelial ovarian cancer. Sharma SK; Suresh MR; Wuest FR Protein Expr Purif; 2014 Oct; 102():27-37. PubMed ID: 25079010 [TBL] [Abstract][Full Text] [Related]
11. Astragalus membranaceus-Derived Anti-Programmed Death-1 Monoclonal Antibodies with Immunomodulatory Therapeutic Effects against Tumors. Chang FL; Tsai KC; Lin TY; Yang TW; Lo YN; Chen WC; Chang JH; Lu MK; Chiou CT; Chen PH; Yen Y; Pan SL; Lee YC Biomed Res Int; 2020; 2020():3415471. PubMed ID: 32190660 [No Abstract] [Full Text] [Related]
12. 4-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody. Cheng K; Feng X; Chai Z; Wang Z; Liu Z; Yan Z; Wang Y; Zhang S Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835603 [TBL] [Abstract][Full Text] [Related]
13. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Jiang Y; Chen M; Nie H; Yuan Y Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929 [TBL] [Abstract][Full Text] [Related]
15. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation. Wang M; Wang J; Wang R; Jiao S; Wang S; Zhang J; Zhang M Commun Biol; 2019; 2():392. PubMed ID: 31667366 [TBL] [Abstract][Full Text] [Related]
16. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH Front Immunol; 2021; 12():654463. PubMed ID: 34054817 [TBL] [Abstract][Full Text] [Related]
17. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas. Wang Y; Wu L; Tian C; Zhang Y Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997 [TBL] [Abstract][Full Text] [Related]
18. Structure and interactions of the human programmed cell death 1 receptor. Cheng X; Veverka V; Radhakrishnan A; Waters LC; Muskett FW; Morgan SH; Huo J; Yu C; Evans EJ; Leslie AJ; Griffiths M; Stubberfield C; Griffin R; Henry AJ; Jansson A; Ladbury JE; Ikemizu S; Carr MD; Davis SJ J Biol Chem; 2013 Apr; 288(17):11771-85. PubMed ID: 23417675 [TBL] [Abstract][Full Text] [Related]